Abstract Background
Sheffield NARCOS (National Adverse Reactions Advisory Service) investigates suspected perioperative anaesthetic reactions using serial tryptase, urinary methylhistamine and clinical information. Further recommendations for additional allergy clinic assessment are provided.
Objective
To establish a robustly measurable protocol for identifying mast cell mediator (MMR) release in this cohort. To compare these thresholds with previous suggested thresholds and algorithms.
Method
A review of 3,455 NARCOS cases referred with a suspected peri-operative allergic reaction.
Tryptase, Urinary methylhistamine (UMH) and clinical details were analysed. 1746 cases were graded using the Ring and Messmer scale. Reaction grade, tryptase and UMH changes were compared with statistical and graphical presentations appropriate to nonnormally distributed measurements using Analyse-IT software.
Results
Sensitive strategies such as 3g/l or 20% are measurable, translatable and would substantially increase detection of potentially relevant changes in tryptases. Adequate quality assurance for low level measurement is needed.
An incremental threshold of 20% would identify potential MMR in an additional 14% of cases with peak tryptase (Tp) between 5 and 14g/L and a further 15% with Tp below 5g/L. Further work is required to establish the diagnostic performance characteristics of this more sensitive approach.
[Type text] UMH also identified up to 120 further cases of potential MMR in absence of tryptase increments.
Conclusion and Clinical Relevance
Future studies should establish and compare the predictive performance characteristics of each strategy against clinical phenotypes. A single agreed definition of positive serial tryptases is needed to enable robust evaluation of diagnostic strategies. This could serve as a harmonised standard for comparative studies of case series from different centres.
[Type text]
Introduction:
The optimum number of tryptase measurements and the best interpretative strategy have not yet been established in peri-operative anaphylaxis. The predominant diagnostic indicator in allergy diagnosis is the clinical history and most tests are thought to be less reliable.
However the tests, and their interpretation, are the most amenable to standardization or harmonization. There have been few large reviews of investigation of perioperative anaphylaxis and the optimal diagnostic test combination remains unknown. The reference diagnosis in those studies is predominantly based on clinical criteria derived from expert opinion and observational studies (WAO International Consensus 201 [1] , National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network [2] and AAGBI Guidelines 2009 [3] . However neither clinical criteria, nor a single robust standardised tryptase interpretation protocol have been subjected to extensive clinical evaluation, and it is very difficult to remove mimics of anaphylaxis from the studies. Allergen triggers are only identified in half of the cases in many series [4] We examined the last 3,455 cases in NARCOS, a national service for the laboratory investigation of adverse anaesthetic drug reactions based in Sheffield, England, to evaluate the performance of serial tryptase and urinary methyl histamine measurement. We compared the results against published criteria for clinical grading of reactions.
Methods

Data
We conducted a retrospective survey of the NARCOS database containing the laboratory and clinical information on all samples referred to Sheffield for NARCOS assessment, including tryptase (T) blood tests or urinary methyl histamine (UMH) tests taken at the time of reaction and 24 hours later. Our required proforma protocol advised serial tryptase measurements immediately, 1-6 hours after reaction and at 24 hours. Most patients had at least 2 serial tryptases (3400), but there was likely to be a wide variation in actual timing, with potential inaccuracies introduced in some during sample labelling, laboratory sample handing and referral onwards. Samples were therefore analysed according to their labelled temporal sequence as T1, T2 or T3.
Analysis
All statistical and graphical analysis was performed using Analyse-IT software V4.0 (Analyse-IT software ltd, Leeds, UK). Pearson's, Spearman's and Kendal's Tau were used for analysis of correlation of Tryptase with grade; Wilcoxon Median Differences for differences in the medians. Median and 95% confidence intervals are plotted because the data is not normally distributed. Analyte measurements, incremental changes and distributions were compared with reaction grade and the number of patients in each cohort who exceeded each threshold incremental changes from peak to trough were tabulated as detailed below. Performance of the threshold incremental strategies in those patients with peak tryptase above and below the "reference range" for both 11.4 (95 th centile) and 14g/L (99 th centile) cut-off levels were compared.
Quality Control
Local tryptase assay validation data (ImmunoCAP, Sweden Diagnostics) demonstrated a coefficient of variation (CV) of 10% or less across the measurable range to 3.5g/L (CV=5%). Therefore a change of tryptase value >=20% can be determined to be the 95% confidence interval for a real and measurable change in this assay; this was the minimum value used to determine a true change in tryptase between samples. For values of less than 3g/L a very rigorous threshold of a 100% increase was used (a 2-fold change) for comparison, to avoid over-interpretation of changes at low levels. The 3g/L threshold has a very similar effect to the (1.2xbaseline plus 2g/L) threshold used in some studies. The upper limit of normal of 14g/ml was validated locally as our 99 th centile reference range (consistent with the manufacturer's data which quotes the 95 th centile as 11.4g/L). Utilising a simple incremental threshold of 3g/L conveniently represents a 300% increase at 1g/L, a 100% increase at 3g/L, a 60% increment at 5g/L, a 26% increment at 11.4 and a 21% increment at 14g/L. It also has the benefit of simplicity.
Throughout the study a single tryptase method (UniCAP, Thermo Scientific, Uppsala, Sweden) and single UMH assay (Pharmacia, Uppsala, Sweden) was used. Tryptase assays performed well in Internal quality control and external quality assurance (UK NEQAS Tryptase) and the between laboratory CV for all available analyser groups in the scheme are comparable and under 10% worldwide.
The urinary methyl histamine assay was validated in house and has a CV of <20% with a locally verified reference range cut-off.
Creatinine-corrected values were reported and positive results defined as greater than 25 g /mmol creatinine (the 95 th centile of normal urines locally validated). Creatinine assays were subjected to satisfactory UK NEQAS assessment throughout, but no EQA currently exists for UMH.
The confounding variable of sample mislabeling in sequence or timing, or variability in individual tryptase kinetics is compensated for by utilising peak to trough changes (p.
Results
Case mix and sampling
3455 cases were referred between January 1998 and May 2015 (1271 males and 2184 females). Twice as many females were referred. 12 cases were excluded because the laboratory failed to send the accompanying samples. 43 cases had single tryptase measurement and were excluded; of which 33% were >=14g/L and 40% >=11.4g/L. 1395/3400 (41% of the referred samples) had had a peak tryptase (Tp) >=14g/L and 45.6%
were >11.4g/L on any one of the three samples (Table 1 & Increments fail to identify the 21 (0.6%) cases where tryptase is >200g/L (above the measuring range of the assay) throughout T1, T2 and T3 samples (i.e. not exceeding a 3g/L or 20% change), and those where the tryptase drops less than 20% in the series.
( Table 1- A single known mastocytosis case was identified at referral, with a clear additional acute change in tryptase levels.
In the absence of any change in referral patterns we can therefore assume that >70% of the entire cohort of referrals would be grade 3-5 reactions. By definition all those cases grading at 3 and above on the ring and Messmer scale will have sufficient features to suggest likely anaphylaxis on the NAIA/FAAN definitions [2] .
Tryptase in different reaction grades
Median Tryptases and incremental tryptase levels rose with grade to grade 4 ( There were no strong correlation between UMH1 and T1 levels overall or in any subgroup (Correlation r all < 0.3) unlike that reported for plasma histamine. The majority of cases had simultaneous evidence of UMH and Tryptase release consistent with previous reports.
UMH is raised without detectable tryptase in 3% of cases.
100-120 cases (3% of the total cohort) were identified where UMH was raised without any detectable incremental change in tryptase (102 for 3g/L incremental threshold, 100 for a 20% increment in tryptase and 120 for a 5g/L threshold).
[ 
What is the smallest incremental change that can be reliably measured?
Rises as small as 20% or 2g/L or ROC thresholds of 5-7g/L have been observed to correlate with anaphylactic reactions in various studies [22, 23] . A compound index (1.2xbaseline + 2g/L) has also been proposed [13] [14] .
No one can reliably measure a change less than twice the routine coefficient of variation (CV) of the assay. Nor can anyone usefully translate a change of less than 2xCV this into clinical practice worldwide. Previous studies deriving ROC curves for Tryptase in small cohorts may not be translatable to other centres [15] , however incremental changes may be 
Correlation between severity and peak tryptase or incremental changes is limited
No strong correlation was seen between peak tryptase and reaction grade overall [20] [14] , implying that tryptase is insensitive or there are non-allergic mimics of all grades of reaction which confound the analysis of all studies. Peak tryptases in all grades of reaction can be small and within the reference range [26] . We show a statistically significant difference in median peak tryptase (or tryptase increment) and grade 1 for all reaction grades, but not between grade 2 and 3, 3 and 4 or grade 1 and 2, possibly due to difficulties in differentiating these grades clinically.
How should Tryptase be used in establishing MMR?
The clinical criteria for anaphylaxis define features that suggest anaphylaxis clinically but do not exclude mimics. To assist in establishing mast cell mediator release in perioperative allergy, we must define a standardized and robust (i.e. translatable) approach to defining changes in markers, since derivation of ROC thresholds in previous cohorts erroneously presupposes definitive diagnosis of drug allergy against a validated reference standard.
The role of tryptase measurement should be to reliably identify those patients with tryptase changes that could represent mast cell mediator release. This large case series suggests that small changes in tryptase are robustly measurable and potentially useful. We establish that a threshold of 20% increment should be the minimum change that can be measured with certainty and that a simple increment of 3 g/L from peak to trough may be a more specific alterative and functions similarly to the (1.2xbaseline+2) algorithm within the reference range. Both require large scale validation since they may identify potential tryptase release in 30-60% of patients with peak tryptases within the reference range. We
show that a few additional cases of likely MMR (3%) can only be detected by UMH analysis.
This may be a useful adjunct for lesser degrees of reaction which are less likely to produce large tryptase increments within the reference range.
No test is without false positives or false negatives; the 3g/L strategy minimizes likely false positivity at lower levels in a similar way to previously suggested algorithms such as (1.2 x baseline) + 2g/L, but the possibility that a 20% rise may of significance at all levels of tryptase remains to be proven. Simple peak tryptase thresholds including T>=14g/L, >=11.4g/L or lower are insensitive, with anaphylaxis and IgE mediated drug reactions seen with peak tryptases much lower than 14g/L [26] [23] [24] . This series confirms that the halflife of tryptase appears to be markedly prolonged in some cases [28] . Despite these caveats, the evaluation of small serial changes is both rational and justified.
[
Type text]
A peak tryptase of >=14g/l is the "correct" threshold for identifying individuals with raised tryptase. 11.4g/l is too sensitive since 2.5% of "normal" people will always exceed this leading to erroneous suspicion of elevation in normal people (Tryptase Kit insert http://www.phadia.com/en-GB/5/Products/ImmunoCAP-Assays/ImmunoCAP-Tryptase/ and Sheffield local validation data). Utilising incremental changes largely negates this disadvantage and gives similar performance irrespective of the threshold used (Tables 1-3 ).
Both strategies are independent of assumptions about accuracy of sample labelling timing or sequence. They make no assumptions about the kinetics of clearance. Laboratories wishing to interpret changes to the 3g/L threshold will need to establish extra IQC strategies for very low values that are not in place routinely.
Increments are less useful in raised tryptases
Utilising increments in tryptase will only miss those cases with slow clearance or inappropriately short intervals between samples. Acute rises always fall, thus tryptase changes of greater than 3g/l can be expected in almost all of these raised samples (except 21 case where tryptase remained >200g/l throughout (i.e. above the upper measuring limit of the assay). 20% increments (or the 1.2xBaseline+2 algorithm) fare slightly less well because the absolute size of a 20% increment at 100g/l is 20g/l and at 50 it is 10g/l.
The role of Urinary Methyl Histamine
We show that raised UMH can be seen in the absence of significantly raised tryptase [38] [13]. Further studies are needed to determine if UMH might identify additional cases of mast cell mediator release [39] [38]. In our cohort, 80% of patients with tryptase release had simultaneous UMH release. Conversely 3% had no evidence of tryptase increments (on any measure) but had positive UMH levels. This additional information may be useful increment in diagnosis and risk assessment.
Summary [Type text]
This data provides the first clear indication of the expected levels of serum tryptase in a large cohort of suspected perioperative anaphylaxis, utilising the only routinely available assay for total tryptase. UK NEQAS External quality assessment data suggest that the majority of participants have assay performance readily able to detect small increments reliably (UK NEQAS Tryptase scheme reports www.immqas.org.uk) meaning that the conclusions are readily translatable to other centres provided laboratories extend their internal controls to reliably report below 3g/L.
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[Type text] Anaphylaxis ungraded = referral stated "anaphylaxis" but without sufficient details for accurate grading.
Data is presented as Box and Whisker plots) with medians (box shoulders = 95 % Confidence intervals), quartiles (outer box represent 25 th and 75 th centiles and max/min ranges. A combination of raised tryptases and incremental changes within then reference range is best.
20% changes are more common within the reference range than 3g/L increments within the reference range, but 5-10% of the raised tryptases do not change by these thresholds.
p >20% = positive change in tryptase from trough to peak of >=20% p>3g/L = change in tryptase level from trough to peak of >=3g/L 
